Cogent Biosciences (COGT) Q4 2025 earnings summary

Executive summary

• Three positive pivotal trials for bezuclastinib in 2025 led to significant regulatory momentum entering 2026, with multiple NDA submissions underway for NonAdvSM, AdvSM, and 2L GIST indications.

• Strong financial position with $900.8 million in cash and equivalents as of December 31, 2025, expected to fund operations into 2028.

• Commercial launch of bezuclastinib anticipated in the second half of 2026, pending FDA approvals.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $900.8 million at year-end 2025, up from $287.1 million at year-end 2024, bolstered by $546.8 million in net proceeds from public offerings.

• R&D expenses were $75.6 million for Q4 2025 and $269.8 million for the full year, up from $62.0 million and $232.7 million in 2024, reflecting expanded clinical and preclinical activities.

• G&A expenses rose to $23.9 million for Q4 2025 and $63.6 million for the year, compared to $11.7 million and $43.3 million in 2024, driven by organizational growth and commercial preparation.

• Net loss was $102.5 million for Q4 2025 and $328.9 million for the year, compared to $67.9 million and $255.9 million in 2024.

Outlook and guidance

• NDA for bezuclastinib in AdvSM on track for submission in 1H 2026; PEAK NDA for 2L GIST expected to complete in April 2026.

• Anticipated FDA acceptance of NonAdvSM NDA in February 2026; commercial launch of bezuclastinib planned for 2H 2026.

• Additional clinical data from PEAK and APEX trials to be presented at major medical meetings in 1H 2026.

• IND submissions and clinical data updates expected for pipeline assets including CGT1815, CGT1145, and CGT4859.